Glenview Trust co Has $16.08 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Glenview Trust co lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,873 shares of the medical instruments supplier’s stock after selling 4,109 shares during the quarter. Glenview Trust co’s holdings in Becton, Dickinson and Company were worth $16,079,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in BDX. Principal Financial Group Inc. raised its stake in shares of Becton, Dickinson and Company by 1.5% during the third quarter. Principal Financial Group Inc. now owns 1,179,715 shares of the medical instruments supplier’s stock worth $284,429,000 after buying an additional 16,918 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at $458,000. Metis Global Partners LLC boosted its position in shares of Becton, Dickinson and Company by 3.2% in the 3rd quarter. Metis Global Partners LLC now owns 10,829 shares of the medical instruments supplier’s stock worth $2,611,000 after purchasing an additional 333 shares during the last quarter. CIBC Asset Management Inc grew its stake in shares of Becton, Dickinson and Company by 5.2% during the third quarter. CIBC Asset Management Inc now owns 56,923 shares of the medical instruments supplier’s stock worth $13,717,000 after purchasing an additional 2,824 shares during the period. Finally, Empirical Finance LLC grew its stake in shares of Becton, Dickinson and Company by 2.2% during the third quarter. Empirical Finance LLC now owns 9,970 shares of the medical instruments supplier’s stock worth $2,404,000 after purchasing an additional 219 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $226.43 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The stock has a market cap of $65.02 billion, a price-to-earnings ratio of 37.61, a PEG ratio of 1.63 and a beta of 0.35. The business has a 50 day simple moving average of $232.78 and a 200 day simple moving average of $232.33. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.84%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company announced that its board has initiated a share repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

A number of brokerages have issued reports on BDX. Barclays raised their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, March 5th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Buy” and a consensus target price of $278.29.

Insider Buying and Selling

In related news, EVP Richard Byrd sold 1,940 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total transaction of $436,325.40. Following the completion of the transaction, the executive vice president now owns 7,411 shares in the company, valued at approximately $1,666,808.01. This represents a 20.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares in the company, valued at $3,807,235. The trade was a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 7,363 shares of company stock worth $1,676,105. 0.36% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.